SeneXta acquires rights to market drug for brain disorders

Published: 29-Jan-2009
Ingredients Sustainability Pharmaceutical

SeneXta Therapeutics has acquired the worldwide exclusive rights to develop and market Methanesulfonyl Fluoride (MSF) for the treatment of brain disorders including Alzheimer's disease and stroke.


SeneXta Therapeutics has acquired the worldwide exclusive rights to develop and market Methanesulfonyl Fluoride (MSF) for the treatment of brain disorders including Alzheimer's disease and stroke.

The Swiss biopharmaceutical company is to collaborate with the University of Texas at El Paso (UTEP) after signing a licensing agreement.

Co-founder and coo Federica Pericle will be UTEP's liaison for SeneXta in El Paso. Dr Pericle is the associate vice president for biotechnology in the Office of Research and Sponsored Projects at UTEP.

SeneXta is the first biotechnology company to be spun off from UTEP intellectual property.

In his research, Dr Donald Moss, professor at UTEP and inventor, discovered that MSF could be an effective treatment for Alzheimer's patients and plays a key role in memory, learning and other brain functions.

"In our preliminary trials, we discovered that MSF produces substantially more cognitive improvement than has been reported for other Alzheimer's drugs in this class," he said. "MSF's unique properties permit delivery of an appropriate therapeutic dose without the side effects of nausea, vomiting and diarrhoea."

SeneXta

T +41 91 924 24 00
info@senexta.com

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  3. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  4. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
Manufacturing

Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS

The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Sustainability

Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold

Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Subscribe now